Company news

Lipocine Inc. news in 2021

Lipocine Inc.'s news releases, calls and decks from 2021, newest first.

View company

Lipocine announces patient dosed in its Phase 2 study with LPCN 1148 for management of liver cirrhosis

December 21, 2021

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021

November 9, 2021

Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH

November 3, 2021

Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

October 31, 2021

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®

October 17, 2021

Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®

September 27, 2021

Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

August 24, 2021

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021

August 4, 2021

Lipocine Announces Settlement With Clarus Therapeutics

July 13, 2021

Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event

June 22, 2021

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

June 13, 2021

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

May 5, 2021

Lipocine Announces Financial Results For The Year Ended December 31, 2020

March 10, 2021

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

March 3, 2021

Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

March 2, 2021

Lipocine Closes Underwritten Public Offering Of Common Stock

January 27, 2021

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

January 25, 2021

Lipocine Announces Launch Of Public Offering Of Common Stock

January 24, 2021

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

January 13, 2021

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

January 11, 2021

Decks in 2021